CytoDyn Inc (OTCMKTS:CYDY) announced that an abstract on the potential of its drug candidate leronlimab for the prevention of HIV has been accepted for presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
The presentation will detail results from a recent study that show leronlimab preventing intrarectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques.
Jonah Sacha, a professor at the Vaccine and Gene Therapy Institute at the Oregon Health & Science University and a senior adviser to CytoDyn, will lead the presentation.
“The acceptance of Dr. Sacha’s late-breaking abstract describing leronlimab’s utility in HIV prevention underscores the potential of leronlimab for treatments beyond suppression of established HIV infection,” CEO Nader Pourhassan said in a statement. “Leronlimab could offer a much needed, simple and long-lasting preventative treatment option for people at risk of HIV infection. The results from this study are extremely promising and further support our efforts to begin clinical trials for leronlimab as a PrEP treatment.”
One problem with current pre-exposure prophylaxis (PrEP) treatments, is the necessity of a daily regimen, Pourhassan said, which makes long-term treatment difficult.
Leronlimab, on the other hand, only needs to be taken monthly.
“The eradication of HIV could get a boost with the use of leronlimab as a once monthly 700 mg injection to prevent HIV,” Pourhassan said. “This could be a powerful paradigm shift in the world of HIV prevention.”
The presentation, titled “CCR5 antibody blockade protects macaques from intrarectal SHIV acquisition,” will take place at 2:30 pm ET on March 9 at the Hynes Convention Center in Boston.
CytoDyn, based in Vancouver, Washington, is also currently working with the Thai Red Cross AIDS Research Centre to conduct a PrEP clinical trial examining leronlimab in people at high risk of HIV infection.
In addition to its potential as a prevention mechanism, leronlimab has earned Fast Track status from the US Food and Drug administration for two other possible uses: a part of a combination therapy for HIV-infected patients and a treatment for metastatic triple-negative breast cancer.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel